Bio-Rad Laboratories (BIO) Expected to Announce Earnings on Thursday

Bio-Rad Laboratories (NYSE:BIO) is expected to be posting its Q1 2025 quarterly earnings results after the market closes on Thursday, May 1st. Analysts expect Bio-Rad Laboratories to post earnings of $1.73 per share and revenue of $573.01 million for the quarter. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, analysts expect Bio-Rad Laboratories to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Bio-Rad Laboratories Price Performance

Shares of BIO opened at $240.50 on Tuesday. Bio-Rad Laboratories has a 1 year low of $215.38 and a 1 year high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The stock has a market cap of $6.74 billion, a P/E ratio of -3.70 and a beta of 1.12. The stock’s 50-day moving average price is $250.16 and its two-hundred day moving average price is $307.44.

Analyst Ratings Changes

BIO has been the topic of several recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Wells Fargo & Company cut their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $380.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.